Feed Additive Mcp,Animal Feed Mcp,Best Quality Mcp Feed Grade Dcp Co., Ltd. , http://www.nsfeedgrade.com
Pharmaceuticals 99.5% Olaparib (Azd-2281) for Antitumor CAS 763113-22-0
Quick Detail:
Product Name
Olaparib
Â
Synonym
Olaparid AZD2281;Olaparib (AZD2281, Ku-0059436);Olaparid
Â
CAS
763113-22-0
Â
MF
C24H23FN4O3
Â
MW
434.469
Â
EINECS
1308068-626-2
Â
Purity
99%
Â
Density
1.43
Â
Appearance
White Powder
Â
Certification
HSE, ISO9001, USP
Â
Standard
Enterprise Standard
Â
Grade
Pharma grade
Â
Usage
oral prescription medicine for women with BRCA-mutated advanced ovarian cancer who have received 3 or more prior chemotherapy medicines
Â
Storage
Discreet packing ways as your requirement, 100% go through.
Â
Packing
Store in cool and dry area and keep away from direct sunlight.
Â
Description
Olaparib is a prescription medicine used to treat advanced Ovarian cancer, It is for patients whose cancerhas certain mutations in the BRCA1 and BRCA2 genes and who have already been treated with at least three other types of chemotherapy.Olaparib is also being studied in the treatment of other types of cancer.
Olapanil is a novel poly-ADP ribose polymerase (PARP) inhibitor, including PARP1, PARP2, and PARP3. PARP mediates a mechanism of DNA repair and plays an important role in DNA damage repair and cell apoptosis. Therefore, the mechanism of DNA damage repair by targeting to cells is mediated by PARP1 and PARCA2 mutant cancer cells Of the critical loopholes in the role, can be used for breast cancer susceptibility gene (BRCA) mutations, platinum-sensitive drug-resistant patients with recurrent severe ovarian cancer maintenance therapy.
Olaparib is a kind of novel poly ADP-ribose polymerase (PARP) inhibitors, including PARP1, PARP2, and PARP3. PARP mediates a DNA-repair mechanism which plays a important role in DNA damage repair and apoptosis, so olaparib specifically targets on the DNA repair mechanism of the targeting cell DNA repair and take effects by attacking the critical vulnerabilities of cancer cells carrying mutations in BRCA1 and BRCA2. Owing to this mechanism, it can be used for the maintenance therapy of patients of severe recurrent ovarian cancer who has breast cancer susceptibility gene (BRCA) mutation as well as being sensitive to platinum drug.
Application
Olaparib acts as an inhibitor of the enzyme poly ADP ribose polymerase (PARP), and is termed a PARP inhibitor. BRCA1/2 mutations may be genetically predisposed to development of some forms of cancer, and may be resistant to other forms of cancer treatment. However, these cancers sometimes have a unique vulnerability, as the cancer cells have increased reliance on PARP to repair their DNA and enable them to continue dividing. This means that drugs which selectively inhibit PARP may be of benefit if the cancers are susceptible to this treatment.
Ovarian cancer forms in the ovary, one of a pair of female reproductive glands where ova, or eggs, are formed.
Lynparza is a poly ADP-ribose polymerase (PARP) inhibitor that blocks enzymes involved in repairing damaged DNA. It is intended for women with heavily pretreated ovarian cancer that is associated with defective BRCA genes."Today's approval constitutes the first of a new class of drugs for treating ovarian cancer," said Richard Pazdur, MD, director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research. "Lynparza is approved for patients with specific abnormalities in the BRCA gene and is an example of how a greater understanding of the underlying mechanisms of disease can lead to targeted, more personalized treatment.
Use
Lynparza is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNA repair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mouse xenograft models of human cancer both as monotherapy or following platinum-based
chemotherapy.
Increased cytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor models with deficiencies in BRCA. In vitro studies have shown that olaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complex, resulting in disruption of cellular homeostasis and cell death.
Advantage
1.Our company is a renowned pharmaceutical manufacturer,specializing in raw steroid powders in Mainland China. It is not only the leading manufacturer of steroids powder and pharmaceutical raw materials in the central area of China but also exports all over the world. All powders are factory directly supplying.
2.Our products have been exported to Germany, Norway, Poland, Finland, Spain, UK, France, Russia, USA,Brazil, Â Mexico, Australia, Japan, Korea, Thailand, Indonesia, Uruguay and many other countries. Monthly output is over 100kgs. We cherish a great number of loyal customers serving in gym fields, athletes fields,medical institution, clinics and so on.
3.Top quality products with the most competitive rate. Free samples are available.Â
4.Well disguised packing. Fast and secure delivery by DHL, TNT, FedEx, HKEMS, UPS, etc.Â
5.Flexible payment terms.
6.Exclusive customer service and 24/7 online timely and helpful After-sale service.
Â